Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus

Arthritis and Rheumatology

Volumn 67, Issue 8, 2015, Pages 2046-2055

  Reddy, Venkat ^a   Cambridge, Geraldine ^a   Isenberg, David A ^a   Glennie, Martin J ^b   Cragg, Mark S ^b   Leandro, Maria ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CELL SURFACE PROTEIN; FC RECEPTOR IIB; OBINUTUZUMAB; OFATUMUMAB; RITUXIMAB; TOSITUMOMAB; ANTIRHEUMATIC AGENT; FC RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL SURFACE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IN VITRO STUDY; INTERNALIZATION; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANK SUM TEST; RHEUMATOID ARTHRITIS; STUDENT T TEST; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; B LYMPHOCYTE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; DRUG RESISTANCE; FEMALE; HUMANS; IN VITRO TECHNIQUES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECEPTORS, IGG; YOUNG ADULT;

EID: 84938071022     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39167     Document Type: Article

References (51)

1. Leandro MJ, Edwards JC, Cambridge G., Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-8.
2. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al., B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-9.
3. Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, et al., Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 2011; 63: 603-8.
4. Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, et al., B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3038-47.
5. Vital EM, Dass S, Buch MH, Rawstron AC, Emery P., An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Ann Rheum Dis 2014. E-pub ahead of print.
6. Rodriguez-Garcia V, Sapeta Dias S, Nguyen H, Pericleous C, Isenberg DA., Longer duration of B cell depletion in patients with systemic lupus erythematosus is associated with a better outcome [abstract]. Ann Rheum Dis 2014; 73 Suppl 2: 359.
7. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ., Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007; 179: 3351-61.
8. Glennie MJ, French RR, Cragg MS, Taylor RP., Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823-37.
9. Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, et al., The 158VV Fcγ receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis 2014; 73: 716-21.
10. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al., The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 455-9.
11. Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW, et al., Genetic linkage of FcγRIIa and FcγRIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 2007; 7: 286-90.
12. Weng WK, Levy R., Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-7.
13. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002; 99: 754-8.
14. Cragg MS, Glennie MJ., Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738-43.
15. Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ., Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2011; 70: 2119-25.
16. Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, Tanaka Y, et al., Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012; 64: 360-70.
17. Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, et al., Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112: 4170-7.
18. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, et al., Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186: 3762-9.
19. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al., Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-10.
20. Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, et al., Fcγ receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011; 118: 2530-40.
21. Tipton TR, Roghanian A, Oldham RJ, Carter MJ, Cox KL, Mockridge CI, et al., Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood 2015; 125: 1901-9.
22. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, et al., Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010; 115: 5191-201.
23. Lee CS, Ashton-Key M, Cogliatti S, Rondeau S, Schmitz SF, Ghielmini, et al., Expression of the inhibitory Fcγ receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98). Br J Haematol 2015; 168: 139-59.
24. Vaughan AT, Iriyama C, Beers SA, Chan CH, Lim SH, Williams EL, et al., Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood 2014; 123: 669-77.
25. Leonard JP, Goldenberg DM., Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007; 26: 3704-13.
26. Leprince C, Draves KE, Geahlen RL, Ledbetter JA, Clark EA., CD22 associates with the human surface IgM-B-cell antigen receptor complex. Proc Natl Acad Sci U S A 1993; 90: 3236-40.
27. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, et al., Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007; 44: 1331-41.
28. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, et al., Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014; 73: 183-90.
29. Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Dorner T., Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008; 67: 450-7.
30. 2 derivative for recruitment of cytotoxic effectors. Mol Immunol 1991; 28: 1243-54.
31. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al., Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393-402.
32. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al., CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383-9.
33. Su K, Yang H, Li X, Li X, Gibson AW, Cafardi JM, et al., Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol 2007; 178: 3272-280.
34. Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, et al., B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010; 335: 213-22.
35. Hou P, Araujo E, Zhao T, Zhang M, Massenburg D, Veselits M, et al., B cell antigen receptor signaling and internalization are mutually exclusive events. PLoS Biol 2006; 4: e200.
36. Edwards JC, Cambridge G., Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 205-11.
37. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA., An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-7.
38. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al., Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
39. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA., Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009; 18: 767-76.
40. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al., Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33.
41. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al., for the LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-26.
42. Reddy V, Jayne D, Close D, Isenberg D., B cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 2013; 15 Suppl 1: S4.
43. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P., Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2993-9.
44. Reddy V, Croca S, Gerona D, De La Torre I, Isenberg D, McDonald V, et al., Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (Oxford) 2013; 52: 951-2.
45. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, et al., Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67: 1724-31.
46. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M., The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010; 6: 280-9.
47. Sibbitt WL Jr, Mathews PM, Bankhurst AD., Natural killer cell in systemic lupus erythematosus: defects in effector lytic activity and response to interferon and interferon inducers. J Clin Invest 1983; 71: 1230-9.
48. Walport MJ., Complement and systemic lupus erythematosus. Arthritis Res 2002; 4 Suppl 3: S279-93.
49. US Food and DrugAdministration. Gazyva (obinutuzumab). URL: http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm373263.htm.
50. Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, et al., Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) 2013; 52: 1313-22.
51. Shan D, Press OW., Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 1995; 154: 4466-75.